Equetro generic
Equetro is an anticonvulsant drug owned by Validus Pharms. It contains carbamazepine as the active ingredient. The drug was first authorised for market use on December 10, 2004. Equetro is available in capsule, extended release; oral dosage forms.
When will Equetro generic be available?
The generic version of Equetro is likely to be released after May 19, 2024. This date is based on the expiry of its patent, US6977253, held by Validus Pharms for the use of Carbamazepine in the treatment of bipolar disorder.
Equetro uses
The recommended initial dose of Equetro is 400mg/day given in divided doses, twice daily. The dose should be adjusted in 200mg daily increments to achieve optimal clinical response. It's typically used for the treatment of bipolar disorder.
Equetro patent expiration
Equetro has a total of 1 drug patent, none of which have expired. The last patent, titled 'Methods for the treatment of bipolar disorder using carbamazepine', is due to expire on May 19, 2024. Below are the details of the patent: